The importance of the immune system in the host response against cancer has been studied for many years. However, treatment of cancer by single immunotherapy has been proven to be only modestly effective. As a result, immunotherapy is only accepted as an option rather than as mainstream treatment of cancer. However, this all changed when a number of breakthrough clinical studies (1,2,3,4) with checkpoint blockers showed that immunotherapy was a viable proposition for mainstream cancer treatment. The rapid increase in knowledge of the immune system and its regulation, and in particular the action of these checkpoint blockers when used in combination, showed hugely improved patient outcomes compared with previous treatments.The hypothesis is that if we can develop a personalised strategy for cancer management of IGS combined with postoperative combination immunotherapy and patient recovery, we would be implementing a revolutionary imaging and therapeutic approach to target distal metastases. This would help by improving better overall survival and QOL for the patient. There is a steady realisation that cancer immunotherapy is going to be a game-changer in terms of treatment and QOL monitoring.
Key scientific objectives:
First key objective
to define subsets of immunoregulatory gene signatures for disease monitoring and to monitor efficacy of immunotherapy combinations incorporated into biomaterial-based platforms
Second key objective
to optimise the biomaterial platform to encapsulate a small library of defined immune reagents for more accurate and timely delivery of the payload to its intended target either as NPs or as MPs
|Third key objective||to optimise the cancer management process by improved treatment options for cancer patients and providing evidence of positive socio-economic outcomes leading to wider patient access to immunotherapy|
|Fourth key objective||to explore how to extend the survival rate in conjunction with QOL after oncology therapy with respect to healthy eating and adequate exercise|